With Investment In Bharat Serum, OrbiMed Speeds Up Its Second Deal In India In Four Months
This article was originally published in PharmAsia News
Executive Summary
MUMBAI - The world's largest healthcare fund OrbiMed seems to be in a hurry to invest in emerging Indian companies. Less than four months after the nearly $5 billion fund made its debut with investments in the Southern Indian clinical research outfit Ecron Acunova, it has now struck its second deal with Bharat Serums and Vaccines - a mid-sized biopharmaceutical unit that mainly manufactures niche life-saving injectable drugs